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Available online 25 September 2006Summary Surgical treatment of malignancies in the oral cavity and subsequent radiotherapy
often result in an anatomic and physiological oral condition unfavorable for prosthodontic reha-
bilitation. The objective of this prospective study was to assess the effect of hyperbaric oxygen
therapy on treatment outcome (condition of peri-implant tissues, implant survival, oral func-
tioning and quality of life) of prosthodontic rehabilitation with implant-retained lower dentures
in radiated head and neck cancer patients 6 weeks and 1 year after placing the new dentures.
The treatment outcome was assessed in a group of 26 head neck cancer patients who were sub-
jected to radiotherapy after tumour surgery. Standardized questionnaires were completed and
clinical and radiographic assessments were performed. After randomization, endosseous Bra˚ne-
mark implants were placed in the anterior part of the mandible either under antibiotic prophy-
laxis (13 patients) or under antibiotic prophylaxis combined with pre and postsurgery
hyperbaric oxygen (HBO) treatment (13 patients). In the HBO and non-HBO group eight implants
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380 P.J. Schoen et al.(implant survival 85.2%) and three implants (implant survival 93.9%) were lost, respectively.
Peri-implant tissues had a healthy appearance in both groups. Osteoradionecrosis developed
in one patient in the HBO group. All patients functioned well with their implant-retained lower
denture. The quality of life related to oral functioning and denture satisfaction were improved
to a comparable extent in the HBO and non-HBO group.
Implant-retained lower dentures can improve the quality of life related to oral functioning
and denture satisfaction in head and neck cancer patients. Adjuvant hyperbaric oxygen therapy
could not be shown to enhance implant survival in radiated mandibular jaw bone.c 2006 Elsevier Ltd. All rights reserved.Introduction
Surgical treatment of malignancies involving the oral cavity
often results in an altered anatomical situation, which may
severely hamper oral functioning. Surgical treatment is of-
ten combined with radiotherapy, which further worsens oral
functioning. Salivary secretion is reduced, and speech,
chewing (mastication), swallowing and aesthetics are often
impaired.1–8 Due to the changed intra-oral conditions
(changed anatomy, oral sequelae of radiotherapy) the pos-
sibilities to obtain proper stability and retention for a man-
dibular prosthesis are seriously at risk.1,9–11 For example,
particularly after radiotherapy, the load-bearing capacity
of both the native and reconstructed tissues is compro-
mised.5,9,12,13 Until recently neither reconstructive surgery
nor conventional prosthodontic techniques were capable
to address these problems successfully.14,15 In prospective
studies with a follow-up of 10 years reporting on the treat-
ment outcome of implant-retained overdentures in healthy
patients suffering from impaired oral functioning due to an
unstable lower denture, implant-retained overdentures
have been proven to be a reliable treatment for problems
involving lack of stability and retention of a lower den-
ture.16 Because of this high success rate a similar prosth-
odontic treatment approach can probably attribute to
better functional results in the oral rehabilitation of head
and neck cancer patients.4,8,9,11,17–26
Nowadays, endosseous implants are used with increasing
frequency for prosthetic support in patients who are treated
for malignancies in the lower region of the oral cav-
ity.10,12,20,26,27 Such implant-based prosthodontic rehabili-
tation is not only performed in patients in whom the
mandible and soft tissues were reconstructed, but also in
patients in whom the mandible was located in the radiation
portals, in spite of the well-documented adverse biologic
changes that occur when soft and osseous tissues have been
exposed to ionizing radiation.5–7,20,28–31 It has been stated
that implant surgery at irradiated sites bears the significant
risk of development of soft and hard tissue necrosis, and
loss of implants.32 Moreover, the appropriateness of using
implants in irradiated patients has been seriously ques-
tioned.18 To reduce these risks, the need for adjunctive pro-
phylaxis with long lasting use of antibiotics and hyperbaric
oxygen (HBO) therapy has been proposed.33
It was advocated to use HBO therapy prior to implant
placement to improve blood flow in compromised areas.
Experimental data reporting increased bone mineralizationand increased biomechanical forces needed to unscrew tita-
nium implants after HBO therapy have given support to this
assumption.34,35 Nevertheless, there is still no consensus or
sound evidence in the literature concerning the benefit of
HBO to improve osseointegration of dental implants in man-
dibles, to reduce loss of implants and to minimise risk of
development of osteoradionecrosis in patients who have
been treated with radiotherapy following cancer treat-
ment.36 Currently, the need for more detailed outcome re-
search has brought up the issue of measuring the quality of
life of cancer patients by assessing their functional status as
well as their physical, social and emotional well-being
through self-administered questionnaires.37
Therefore, the objective of this prospective study was to
assess the effect of HBO therapy on treatment outcome
(condition of peri-implant tissues, implant survival, oral
functioning and quality of life) of prosthodontic rehabilita-
tion with implant-retained lower dentures in irradiated
head neck cancer patients.
Material and methods
Patients
In 2000 all consecutive edentulous patients that had been
treated for a first malignancy in the head and neck region
(squamous cell carcinoma of tongue, floor of the mouth,
mandibular gingiva, buccal mucosa or oropharynx) with
either radiotherapy or a combination of surgery and radio-
therapy were screened to be included in this study. The pa-
tients had been admitted between 1990 and 2000 to the
Head and Neck Oncology Group of the Groningen University
Medical Center, the Netherlands. In total 72 patients were
screened by a maxillofacial surgeon (PJS) and prosthodon-
tist (HR). Prosthetic problems related to lack of stability
and retention of the lower denture were evaluated. In addi-
tion, it was required that little or no improvement could be
expected from making a new set of dentures. Forty eight of
these 72 patients had problems with functioning with their
lower denture. Of this group of 48 patients, 26 patients
wanted to participate in this study, while the other 22 pa-
tients did not want additional non-oncologic surgical inter-
ventions as is implant placement. Patients who agreed
with treatment were randomized in two groups. These pa-
tients either received peri-operative antibiotics or antibiot-
ics in combination with HBO treatment. Informed consent
was obtained from all patients.
Effects of hyperbaric oxygen therapy 381Treatment
All patients underwent both tumour surgery and radiotherapy
at the University Medical Center Groningen. Dosimetry was
performed to calculate the dose at the implant locations.
The cumulative absorbed dose was calculated using the CT
data available for the treatment planning. The anterior part
of the mandible was drawn as region of interest, the
treatment plans were calculated using radiotherapy treat-
ment-planning system,Helax-TMS6.1B (Nucletron, TheNeth-
erlands). The maximum dose in the region of interest was
used as the cumulative absorbeddose in that region (Table 1).
After randomization with regard to age, gender, site and
stage of the primary tumour, reconstructive procedure and
total dose of irradiation, 13 patients (group 1) received peri-
operative antimicrobial prophylaxis with broad-spectrum
antibiotics (cefradine 1 g, three times daily during 2 weeks).
The other 13 patients (group 2) received 20 HBO treatments
of 100% oxygen at 2.5 atmospheres for 80 min (4 periods of
20 min) before implant surgery, and 10 HBO treatments of
100% oxygen at 2.5 atmospheres for 80 min after implant
surgery in addition to the antimicrobial prophylaxis as ap-Table 1 Patient characteristics regarding age, sex, primary tum
and implant placement in years, number of implants, number of l
Age Sex Primary tumour Stage T
58 M Mandibular gingiva T4N0
75 M Mandibular gingiva T4N0
49 M Mandibular gingiva T4N1
63 M Mandibular gingiva T4N0
67 F Tongue T3N1
48 M Tongue T3N1
58 M Floor of mouth T4N0
50 F Floor of mouth T2N0
58 M Tongue/floor of mouth T2N2
54 F Tongue/floor of mouth T2N1
50 M Oropharynx T4N3
53 M Oropharynx T2N0
67 F Oropharynx T4N0
68 F Mandibular gingiva T4N0
55 F Mandibular gingiva T4N0 1
55 M Mandibular gingiva T4N1
62 F Tongue T2N0
55 M Tongue T4N0
63 M Tongue T3N1
54 M Floor of mouth T2N1
58 M Floor of mouth T2N1
64 M Floor of mouth T3N2b
64 M Oropharynx T4N0
71 F Oropharynx T4N0
71 F Tongue T2N1
65 M Oropharynx/base of tongue T4N2c
a TD: cumulative dose in gray at the implant site.
b TI: time interval between end of radiotherapy and placement of im
c NI: number of implants.
d IL: number of implants lost.
e Status: Died TR: died due to tumour related disease. Died NTR: di
supported prosthesis could be made because of development of osteoplied in the non-HBO group. A computer program was used
for randomization of the patients.38 HBO treatments were
performed at the Institute for Hyperbaric Oxygen Treat-
ment in Hoogeveen, the Netherlands. All patients started
with broad-spectrum antibiotics 1 day before implant sur-
gery and continued for 2 weeks.
In all patients the implants (Bra˚nemark Implants, Nobel-
biocare, Gothenburg, Sweden; Table 1) were placed in the
interforaminal region of the mandible as a one-stage surgi-
cal procedure by the same surgeon (GM). The most lateral
implants were placed at least 5 mm medially of the mental
foramen and there was an equal distance between the
implants. After an osseointegration period of six months,
fabrication of implant-retained prostheses was started
according to standard clinical and laboratory procedures.
A new maxillary complete denture and a mandibular over-
denture supported by an individual made bar-clip construc-
tion were fabricated. All prostheses were made by one
experienced prosthodontist (HR). Home care instructions
with regard of maintenance of the prosthesis and peri-
implant tissues around the implants consisted of daily
mechanical cleaning of the implants and connection barour, staging, total dose, elapsed time between radiotherapy






59 6 5 1 Yes
58 1 4 – Yes
60 2 6 – Yes
61 1 4 1 Yes Died NTR
55 9 4 – Yes
66 3 4 1 Yes
60 2 4 – Yes
57 1 3 – Yes
70 10 4 – Yes
60 2 4 4 Yes No prosthesis
63 6 4 1 Yes Died NTR
52 3 4 – Yes Died NTR
66 3 4 – Yes Died TR
60 3 5 2 No
16 1 4 – No
63 1 2 – No
64 6 4 – No
52 3 4 – No
46 2 4 1 No
60 9 2 – No
72 8 4 – No Died TR
60 1 4 – No
50 3 4 – No
50 6 4 – No Died TR
50 3 4 – No Died TR
66 6 4 – No Died NTR
plants in years.
ed due to non-tumour related disease. No prosthesis: no implant
radionecrosis and loss of all implants.
382 P.J. Schoen et al.with a soft tooth brush and interdental brushes or Superfloss
(Oral B, Frankfurt am Main, Germany).
Clinical assessments
The clinical assessment included dental status, oral condi-
tion and prosthetic rehabilitation. Postoperative complica-
tions and implant survival were recorded from the time of
surgery until 1 year after placement of the prostheses. Peri-
odontal indices were assessed six weeks after placing the
new dentures (T1) and 12 months later (T2). The periodontal
indices included the following parameters: plaque index,39
bleeding index,39 gingival index,40 probing depth, and im-
plant mobility.41 Probing depth was measured at four sites
of each implant (mesially, labially, distally, lingually) by
using a periodontal probe (Merit B, Hu Friedy, Chicago,
USA) after removal of the bar; the distance between the
marginal border of the mucosa and the tip of the periodon-
tal probe was scored as the probing depth. Mobility of the
implants was determined quantitatively by Perio Test Val-
ues, also after removal of the bar. All clinical assessments
were performed by the investigator (PJS) who was not in-
volved in treatment of the patients.
Radiographic analysis
The oblique lateral radiographic technique was used to
determine resorption patterns of the edentulous mandible
and to study bone (re)modeling processes following the
placement of dental implants.42 At the start of prosthetic
loading (T1) and after 12 months (T2), four oblique lateral
radiographs were made to depict the lateral and frontal
parts of the mandible. The mesial/distal bone height was
defined as the distance between the apex of the implant
and the marginal bone level at the mesial/distal side of
the implant. The measurements were executed using a spe-
cially made transparent template in which a millimetre ru-
ler was engraved. In this way, bone height could be
measured in a reproducible manner in all instances. Dis-
tances were assessed to the nearest 0.5 mm.Functional assessments and quality of life
Preoperatively the patients (T0) were asked to fill out ques-
tionnaires regarding oral functioning and quality of life. The
questionnaires were administered by the investigator (PJS)
who was not involved in treatment of the patients. Similar
questionnaires had to be completed six weeks (T1) and
12 months (T2) after placing the new dentures. At the same
time points, the patients also had to complete question-
naires regarding denture satisfaction and the impact of den-
ture related problems on social activities:
Quality of Life (QoL) was assessed using the core ques-
tionnaire (EORTC QLQ-C30) and the head and neck module
(EORTC H&N35) of the European Organization for Research
and Treatment of Cancer (EORTC). The core questionnaire
consisted of 30 questions (items) exploring six multi-item
functional scales (physical function, role function, social
function, emotional function, cognitive function, and over-
all health status/QoL), three multi-item symptom scales
(pain, fatigue and emesis) and six single items (bowel func-tion, breathing, appetite, sleep disorders and economic se-
quelae.43 The head and neck module contained 35 items
exploring symptoms and side effects of treatment. It com-
prised six multi-item scales (pain, swallowing, senses,
speech, social eating, social contact, sexuality) and seven
single items.44 All scores ranged from 0 to 100. With regard
to the functional scales of the EORTC QLQ-C30, higher
scores meant higher QoL and better results. In the symptom
scales and the single-item scales of the EORTC QLQ-C30,
higher levels represent higher degrees of problems caused
by the symptom, so that the best result in these scales
was a score of 0. The scores of the H&N module finally also
have a range from 0 to 100 with higher scores representing
higher degrees of problems and good results showing low
scores.
The physical, psychological and social impact of oral dis-
orders was assessed using the Oral Health Impact Profile
(OHIP) questionnaire comprising of six multi-item
scales.45,46 Responses on each item ranged from ‘very of-
ten’ (score 4) to ‘never’ (score 0). Adding the scores results
in a total score per scale; a high score means a high impact
on the aspect concerned. The six OHIP scales assessed were
functional limitation (9 items, range 0–36), physical pain
(9 items, range 0–36), physical disability (9 items, range
0–36), psychological discomfort (5 items, range 0–20), psy-
chological disability (6 items, range 0–24) and social
disability (5 items, range 0–20). In addition the OHIP-14
(14 items, range 0–56), a short form of the original OHIP-
49 measuring the overall-impact of dental problems, was
used.47
Denture satisfaction was assessed using a validated ques-
tionnaire consisting of eight separate items focusing on the
function of upper and lower dentures, and on specific fea-
tures such as esthetics, retention and functional comfort.48
Each item was presented with a five point rating scale on
which the patient indicated the extent he or she was
(dis)satisfied. A high score indicated more dissatisfaction.
Overall denture satisfaction was expressed on a 10-point
rating scale (0–10), ‘0’ being completely dissatisfied, ‘10’
being completely satisfied.
Subjective chewing ability was assessed by using a 9-item
questionnaire on which the patient could rate on a 3-point
scale her/his ability to chew different kinds of food.49
The impact of denture problems on social activities, such
as going out, and contacting and visiting people, was as-
sessed with the Groningen Activity Restriction Scale Den-
tistry (GARS-D).50 GARS-D is an 11-item scale yielding a
score ranging from 0 to 22; the higher the score, the larger
the impact on social activities.Data analysis
The data were evaluated using the Statistical Package Social
Sciences (SPSS, version 11.5 for Windows, SPSS Inc., Chi-
cago, USA). Changes were stated as significant if p < 0.05.
Because the data was not normally distributed, non-para-
metric tests were used; the Wilcoxon signed ranks test for
two related samples when comparing results within groups
in time. The Mann–Whitney U test for two independent
samples was used when comparing patients treated with
and without HBO at the same time.
Effects of hyperbaric oxygen therapy 383Results
Patients
In total 26 patients, 17 men and 9 women (mean age
60.1 ± 7.5 years; range 47–77 years), were included (Table
1). The interforaminal area of the lower jaw in which the
implants were inserted received a cumulative radiation dose
of at least 46 Gy (mean 61.4 ± 12.9 Gy, range 46–116 Gy) at
the implant site. Two patients past away during the osseo-
integration because of medical complications not related
to the implant surgery. In 23 patients implant-retained
overdentures were fabricated, while in one patient no pros-
thesis could be made because of loss of all implants related
to development of osteoradionecrosis. At the 1 year evalua-
tion, six patients were lost to follow-up due to serious ill-
ness not related to implant surgery.
Clinical assessments
All patients receiving HBO therapy were able to fulfill the
complete treatment without problems. In all patients, the
interforaminal bone volume was sufficient to enable reliable
placement of implants (Fig. 1). No postoperative complica-Figure 1 A 48-years old male patient previously treated
because of a T3N1 squamous cell carcinoma of the tongue with
local excision of the tumour and a unilateral supra-omohyoid
neck dissection. Six weeks after surgery, a fractionated
radiotherapy scheme was started up to a cumulative dose of
66 Gy. Three years later four dental implants were inserted in
the mandible after 20 HBO treatments before placement of the
implants and 10 HBO treatments after implant surgery. In
addition peri-operative antimicrobial prophylaxis with broad-
spectrum antibiotics was applied. (a) Clinical intra-oral view
showing the four implants connected with a bar. (b) Orthopan-
tomogram 1.5 years after surgery showing the four implants and
the bar.tions occurred related to implant surgery. Of the total 103
placed implants, 11 implants were lost in seven patients
(Table 1), namely eight implants before loading and three
after loading. At the one-year evaluation, in two patients
treated without HBO three implants were lost (implant sur-
vival rate 93.9%) and in five patients treated with HBO eight
implants were lost (implant survival rate of 85.2%). The dif-
ference between the groups was not significant. Moreover,
loss of implants was not related to the time interval be-
tween radiotherapy and placement of implants.
No significant difference was found in percentage of suc-
cessful dentures on implants between the both groups, nei-
ther existed a correlation between the reconstructive
procedures (i.e. primary closure, split skin graft, soft tissue
free flap or vascularized free flap), irradiation dose, implant
survival and success of the denture. Osteoradionecrosis
developed in one patient in the HBO group.
The mean scores on the indices for the peri-implant
parameters were low at all evaluation periods and did not
change significantly over time (Table 2), except for pocket-
depth in the HBO group where a significant increase was ob-
served. There was no significant difference in peri-implant
health between both groups except for plaque-index at
the 1-year interval.Radiographic evaluation
During the first year after loading a minor, although signifi-
cant, peri-implant bone loss of 0.7 ± 0.6 mm was observed
at all implant sites (0.6 ± 0.6 mm and 0.7 ± 0.7 mm at the
HBO and non-HBO sites, respectively). No significant differ-
ence in peri-implant bone loss was observed between the
HBO and non-HBO patients.Quality of life
All functional scales of the EORTC QLQ-C30 showed a strong
tendency towards improvement especially in the non-HBO
group, but only emotional functioning improved signifi-
cantly. The symptom scales and single items showed no
changes except for a temporary increase on dyspnoea at
T1 in the HBO group and a decrease on pain at T1 in the
non-HBO group (Table 3). The items of the head and neck
module showed no significant changes. Also no improvement
could be observed from HBO therapy on dryness of the
mouth (Table 4). The results of the Oral Health Impact Pro-
file questionnaire showed a beneficial effect of the treat-
ment on psychological discomfort and strong tendencies
towards improvement on all other scales especially in the
non-HBO group (Table 5).Functional assessments and denture satisfaction
The questionnaires regarding denture satisfaction showed
significant improvement in time, but no differences be-
tween the HBO and non-HBO group were seen. The impact
of denture problems on social activities, as assessed with
the GARS-D, and the ability to chew different kind of foods
showed tendencies towards improvement for both groups
(Table 6).
Table 2 Peri-implant parameters
HBO Non-HBO
T1 T2 T1 T2
Plaque-index (score 0–3) 1.5 ± 0.8 1.7 ± 1.0 0.9 ± 0.6 0.8 ± 0.8a
Calculus (score 0–1) 0.0 ± 0.1 0.0 ± 0.0 0.1 ± 0.3 0.1 ± 0.3
Bleeding-index (score 0–3) 1.4 ± 0.7 1.7 ± 0.4 1.0 ± 0.6 1.6 ± 0.4
Gingiva-index (score 0–3) 0.3 ± 0.5 0.6 ± 0.8 0.4 ± 0.5 0.5 ± 0.4
Pocketdepth (mm) 2.6 ± 1.5 3.4 ± 0.9b 2.5 ± 0.8 3.0 ± 0.7
Width attached gingiva (score 0–3) 1.6 ± 0.9 1.5 ± 0.7 1.9 ± 0.5 1.6 ± 0.9
Periotest (scoring range: 8 to 50) 1.8 ± 2.8 1.2 ± 3.6 1.1 ± 10.1 3.1 ± 5.6
A higher score indicates more plaque, calculus, bleeding, pocketdepth, width of attached gingiva and less stability of the implant
(periotest).
HBO: patients with HBO-therapy; non-HBO: patients without HBO-therapy.
T1: six weeks after placing new dentures; T2: twelve months after placing new dentures.
a Significant difference between HBO and non-HBO.
b Significant difference between T1 and T2.
Table 3 Results of the functional scales, symptom scales and single items of EORTC QLQ-C30
HBO Non-HBO
T0 T1 T2 T0 T1 T2
Global health status/quality of life 71.4 ± 13.5 59.4 ± 25.8 66.7 ± 13.6 79.2 ± 20.9 85.4 ± 24.3 84.3 ± 19.7
Physical functioning 82.9 ± 17.6 78.3 ± 19.1 78.1 ± 23.9 86.7 ± 14.7 84.2 ± 12.3 86.7 ± 16.7
Role functioning 85.7 ± 17.8 60.4 ± 30.8 81.0 ± 26.2 72.9 ± 36.7 87.5 ± 23.1 83.3 ± 23.6
Emotional functioning 84.5 ± 24.3 75.0 ± 22.3 91.7 ± 9.6b 80.2 ± 30.5 94.8 ± 11.7c 89.8 ± 10.8
Cognitive functioning 85.7 ± 17.8 79.2 ± 29.2 78.6 ± 18.5 87.5 ± 24.8 87.5 ± 14.8 88.9 ± 18.6
Social functioning 90.5 ± 18.9 77.1 ± 19.8 85.7 ± 26.2 77.1 ± 36.7 89.6 ± 17.7 87.0 ± 21.7
Fatigue 22.2 ± 24.8 27.8 ± 22.2 25.4 ± 22.9 12.5 ± 20.1 15.3 ± 16.7 14.8 ± 20.8
Nausea and vomiting 0.0 ± 0.0 12.5 ± 29.2 14.3 ± 24.4 0.0 ± 0.0 0.0 ± 0.0 1.9 ± 5.6
Pain 7.1 ± 18.9 18.8 ± 18.8 19.0 ± 20.2 16.7 ± 23.6 2.1 ± 5.9a,c 5.6 ± 11.8
Dyspnoea 0.0 ± 0.0 29.2 ± 21.4a 9.5 ± 16.3 20.8 ± 30.5 12.5 ± 17.3 14.8 ± 17.6
Insomnia 19.0 ± 26.2 29.2 ± 41.5 11.1 ± 27.2 20.8 ± 39.6 12.5 ± 24.8 18.5 ± 24.2
Appetite loss 14.3 ± 26.2 20.8 ± 30.5 23.8 ± 25.2 12.5 ± 24.8 4.2 ± 11.8 11.1 ± 23.6
Constipation 4.8 ± 12.6 8.3 ± 15.4 9.5 ± 25.2 8.3 ± 15.4 4.2 ± 11.8 0.0 ± 0.0
Diarrhoea 4.8 ± 12.6 8.3 ± 15.4 19.0 ± 32.5 4.2 ± 11.8 0.0 ± 0.0 3.7 ± 11.1
Financial difficulties 4.8 ± 12.6 20.8 ± 35.4 9.5 ± 16.3 16.7 ± 35.6 16.7 ± 35.6 14.8 ± 33.8
HBO: patients with HBO-therapy; non-HBO: patients without HBO-therapy.
T0: preoperatively; T1: six weeks after placing new dentures; T2: twelve months after placing new dentures.
a Significant difference T1 versus T0.
b Significant difference T2 versus T1.
c Significant difference between HBO and non-HBO at the same point in time.
384 P.J. Schoen et al.Discussion
Surgical treatment of malignancies in the oral cavity and
subsequent radiotherapy often result in an anatomic and
physiological oral condition unfavorable for prosthodontic
rehabilitation. This unfavorable oral condition may have a
negative effect on both denture satisfaction and quality of
life in general. As shown in this study, many of these prob-
lems can, at least in part, be diminished by the use of an im-
plant-retained lower denture. In this respect, the question
of whether or not HBO increases implant success in irradi-
ated patients is important. The results of this study did
not show a beneficial effect of HBO with regard to implantsurvival and prevention of osteoradionecrosis when com-
pared to non-HBO treated patients who received only the
prophylactic antibiotics. Unfortunately, it was not possible
to assess the value of prophylactic antibiotics in our patient
cohort too, because it is common sense to apply antibiotic
prophylaxis in patients subjected to surgical treatment
(including extractions and implant placement) in irradiated
areas. Although not evidence based, there is strong clinical
support for the use of antibiotic prophylaxis to minimise risk
of development of osteoradionecrosis.51,52 Because of the
high morbidity of osteoradionecrosis when it develops, it
is for ethical reasons not allowed to perform such a control
experiment in this patient cohort.
Table 4 Results of the multi-item scales and single items of EORTC QLQ-H&N35
HBO Non-HBO
T0 T1 T2 T0 T1 T2
Pain 9.5 ± 12.2 22.9 ± 23.9 20.2 ± 18.5 13.5 ± 17.2 9.4 ± 12.9 14.8 ± 12.3
Swallowing 28.6 ± 23.0 30.2 ± 25.9 34.5 ± 27.0 22.9 ± 15.9 16.7 ± 23.6 23.1 ± 15.5
Senses problems 23.8 ± 21.2 33.3 ± 37.8 38.1 ± 31.5 33.3 ± 28.2 27.1 ± 28.1 27.8 ± 30.0
Speech problems 6.3 ± 8.7 25.0 ± 20.4 12.7 ± 16.3 22.2 ± 27.2 18.1 ± 27.2 11.1 ± 16.7
Trouble with social eating 21.4 ± 17.9 33.3 ± 34.8 27.4 ± 17.8 36.5 ± 37.3 29.2 ± 28.9 23.1 ± 33.3
Trouble with social contact 1.9 ± 3.3 7.5 ± 14.0 6.7 ± 10.2 13.3 ± 21.7 7.5 ± 16.1 2.2 ± 3.3
Less sexuality 9.5 ± 25.2 16.7 ± 25.2 28.6 ± 35.6 31.3 ± 44.0 10.0 ± 14.9 19.0 ± 33.9
Teeth 22.2 ± 34.4 29.2 ± 27.8 28.6 ± 23.0 23.8 ± 41.8 12.5 ± 24.8 22.2 ± 33.3
Opening mouth 38.1 ± 40.5 25.0 ± 29.5 23.8 ± 25.2 37.5 ± 33.0 25.0 ± 23.6 29.6 ± 30.9
Dry mouth 52.4 ± 42.4 62.5 ± 27.8 61.9 ± 40.5 58.3 ± 46.3 54.2 ± 39.6 51.9 ± 37.7
Sticky saliva 19.0 ± 32.5 20.8 ± 30.5 23.8 ± 31.7 50.0 ± 47.1 50.0 ± 39.8 51.9 ± 33.8
Coughing 4.8 ± 12.6 16.7 ± 25.2 19.0 ± 26.2 4.2 ± 11.8 12.5 ± 17.3 14.8 ± 24.2
Felt ill 0.0 ± 0.0 16.7 ± 25.2 14.3 ± 26.2 4.2 ± 11.8 4.2 ± 11.8 7.4 ± 22.2
Pain killers 28.6 ± 48.8 25.0 ± 46.3 42.9 ± 53.5 12.5 ± 35.4 25.0 ± 46.3 22.2 ± 44.1
Nutritional supplements 28.6 ± 48.8 25.0 ± 46.3 28.6 ± 48.8 25.0 ± 46.3 37.5 ± 51.8 22.2 ± 44.1
Feeding tube 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Weight loss 0.0 ± 0.0 12.5 ± 35.4 14.3 ± 37.8 12.5 ± 35.4 12.5 ± 35.4 11.1 ± 33.3
Weight gain 0.0 ± 0.0 25.0 ± 46.3 0.0 ± 0.0 37.5 ± 51.8 0.0 ± 0.0 11.1 ± 33.3
HBO: patients with HBO-therapy; non-HBO: patients without HBO-therapy.
T0: preoperatively; T1: six weeks after placing new dentures; T2: twelve months after placing new dentures.
Table 5 Results of the Oral Health Impact Profile (OHIP)
HBO Non-HBO
T0 T1 T2 T0 T1 T2
OHIP14 18.3 ± 9.9 20.7 ± 15.3 15.0 ± 7.3 23.9 ± 17.1 13.7 ± 14.1 12.7 ± 9.7
Functional limitation 16.9 ± 9.6 17.0 ± 8.0 14.3 ± 4.9 18.0 ± 9.3 11.7 ± 6.6 12.1 ± 7.4
Physical pain 13.6 ± 11.0 11.3 ± 8.0 8.3 ± 5.4 12.5 ± 10.3 7.9 ± 9.3 8.6 ± 5.6
Physical disability 18.3 ± 8.1 15.9 ± 12.0 16.1 ± 9.2 19.7 ± 9.7 11.0 ± 9.8 11.1 ± 9.1
Psychological discomfort 4.9 ± 4.7 4.6 ± 3.6 2.1 ± 2.1 8.3 ± 8.0 1.3 ± 2.4a,c 1.3 ± 1.8b
Psychological disability 2.7 ± 3.9 5.8 ± 5.3 2.2 ± 3.4 6.9 ± 8.4 2.8 ± 5.1 1.2 ± 2.7
Social disability 2.3 ± 3.5 3.6 ± 4.1 0.8 ± 1.6 6.5 ± 8.0 3.0 ± 5.3 1.8 ± 4.0
HBO: patients with HBO-therapy; non-HBO: patients without HBO-therapy.
T0: preoperatively; T1: six weeks after placing new dentures; T2: twelve months after placing new dentures.
a Significant difference T1 versus T0.
b Significant difference T2 versus T0.
c Significant difference between HBO and non-HBO at the same point in time.
Table 6 Results of the functional assessments and denture satisfaction
HBO Non-HBO
T0 T1 T2 T0 T1 T2
GARS-D 3.1 ± 3.1 7.4 ± 7.8 5.3 ± 5.5 8.0 ± 7.9 5.3 ± 6.5 4.3 ± 7.4
Overall denture satisfaction 4.4 ± 2.3 6.8 ± 1.6 7.0 ± 2.1 4.9 ± 2.6 7.1 ± 2.6a 7.8 ± 1.3b
Denture satisfaction 28.0 ± 6.8 16.9 ± 4.6a 17.7 ± 6.2 26.0 ± 9.7 13.3 ± 4.3a 13.6 ± 4.6b
Chewing/eating 13.3 ± 2.5 11.6 ± 6.5 11.0 ± 5.4 13.4 ± 3.5 10.7 ± 4.8 10.0 ± 5.6
HBO: patients with HBO-therapy; non-HBO: patients without HBO-therapy.
T0: preoperatively; T1: six weeks after placing new dentures; T2: twelve months after placing new dentures.
a Significant difference T1 versus T0.
b Significant difference T2 versus T0.
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icant patient compliance and involves financial costs per pa-
tient treatment. In addition, HBO therapy is not without
risks and adverse effects like barotrauma, particularly of
the middle ear, O2 seizures or a change in the refractive
power of the lens.53 There are many papers written about
the subject, including thorough review articles, but ran-
domized controlled trials are lacking.36,54 The randomized
controlled trial, more than any other study design provides
the most reliable evidence for treatment effectiveness.53
Based on the available literature, no conclusions could be
stated about the indications and usefulness of HBO for irra-
diated patients undergoing implant therapy. This is in accor-
dance with the results of our randomized clinical trial.
Although the study population of our trial is rather small,
the outcome of this randomized clinical trial clearly shows
that a very large population is needed to detect a clinical
significant difference between HBO treated and non-HBO
treated patients with regard to implant success and prophy-
laxis of osteoradionecrosis, if any. In this respect it even can
be doubted if a randomized controlled trial with larger
groups will give results in favor of HBO when looking at
the tendencies in this study.
The difference in implant survival between the HBO and
non-HBO treated patients as observed in this trial seems
remarkable, but is mainly caused by one HBO treated pa-
tient who developed osteoradionecrosis and subsequently
lost all four implants. However, also during the follow-up
of the patients included in this trial beyond the observation
period of this study, again patients in the HBO group tended
to lose implants at a higher rate than patients treated with-
out HBO resulting in a three years implant survival rate of
81% and 92%, respectively. Moreover, in contrast to what
has been posed in the literature no relation was found be-
tween the loss of implants and the time interval between
radiotherapy and placement of implants in our study.55
However, if the observation of Granstrom that implant loss
increases with time elapsed between end of radiotherapy
and implant placement is real, this effect might be masked
in our study by the too small sample size to confirm or reject
this conclusion.
It often has been suggested that HBO may exert a posi-
tive effect on irradiation-induced oral dryness, but no clin-
ical trials are available in the literature supporting such an
assumption to date. This is in line with a study assessing
the efficacy of HBO in the management of patients with
radiation-induced late side effects revealing a low response
rate of salivary symptoms to HBO treatment.56 Our study
confirmed the latter data as HBO treated patients reported
a comparable level of oral dryness as non-HBO treated
patients.
In general, we were surprised by the better performance
of patients not treated with HBO on almost every aspect of
this controlled trial. A possible explanation could be the ex-
tra treatment burden encompassing thirty sessions of HBO.
As patients may become tired of treatment, especially when
there is apparently not a very great effect to be expected on
the treatment outcome, such an effect might negatively
influence quality of life measurements and denture satisfac-
tion in HBO treated patients.
In this study, a negligible effect of rehabilitation of oral
function on quality of life was observed. Many of the instru-ments available for measuring quality of life in head and
neck cancer patients are probably not sensitive enough to
measure such an effect. This conclusion is in line with a re-
cent consensus report on oral and facial rehabilitation also
noting that the ‘‘quality of life in oral and facial rehabilita-
tion is largely unresearched. Prospective studies that quan-
tify quality of life related to surgical measures are
lacking’’.57 This observation was one of our reasons to per-
form our randomized clinical trial. The consensus continued
‘‘There is an apparent need to develop and employ specific
instruments for the assessment of quality of life in oral and
facial rehabilitation and to apply them in prospective tri-
als’’.57 Again this was one of the main topics of our re-
search. Moreover, ‘‘Health-related quality of life
measurements in this respect need a specific questionnaire
with appropriate sensitivity and responsiveness. This is sup-
posed to be in addition to existing validated questionnaires
tapping broader concepts, e.g. head- and neck-specific
questionnaires’’.57 This was our reason for combining
EORTC QLQ-C30 with EORTC H&N35, OHIP, (overall) denture
satisfaction, subjective chewing ability and GARS-D. With
exception of the EORTC H&N35, the more head- and neck-
specific questionnaires showed some significant changes,
while the applied treatment did not result in a change in
the overall quality of life as measured with e.g. the EORTC
QLQ-C30 and EORTC H&N35. A major reason that even the
more specific questionnaires did not detect large changes
in the quality of life might be that the oncology treatment,
in particular radiotherapy, have resulted in so much distress
and morbidity (such as worries about survival, fatigue, xero-
stomia, trismus, loss of taste, swallowing disorders, prob-
lems with speech) that wearing an implant-retained lower
denture might have minor to no impact on overall quality
of life. However, when assessing the more specific oral com-
plaints that are related to denture problems, it was obvious
that most patients reported significant improvement of
their denture comfort as is obvious from the denture satis-
faction scores. Thus when assessing the impact of oral
treatments on the quality of life, one has to ask those ques-
tions regarding quality of life that focus on the oral compo-
nent. The EORTC H&N35 seems to be not as specific as
needed in this respect and the OHIP, GARS-D, denture satis-
faction and chewing ability scores are just too specific for
the oral component thus not reflecting an impact on the
more general quality of life. Thus, there is still a need for
developing more specific questionnaires addressing the im-
pact of the oral component on quality of life.
This study shows that radiotherapy should not be con-
sidered an absolute contraindication for implant therapy
in the mandible. According to our randomized clinical
trial, HBO therapy does not influence the failure rate of
implants inserted in mandibles when compared to patients
treated without HBO therapy. Therefore, the potential
benefit of preventive HBO therapy, as assumed by some
authors in the literature could not be confirmed.55,58 The
latter authors based their conclusions on retrospective
studies. Moreover, our findings are in line with the Coch-
rane review of Coulthard indicating that there is insuffi-
cient evidence for a beneficial effect of HBO with regard
to implant survival.53 Future research with larger groups
of patients, probably multi-centred, should address
whether there is potential benefit of hyperbaric oxygen
Effects of hyperbaric oxygen therapy 387treatment with regard to implant survival in irradiated pa-
tients, if any. Such a beneficial effect could not be shown
in our study, but the study sample was too small to make
such a firm conclusion against a potential benefit of HBO
therapy with regard to implant survival. Finally, one has
to keep in mind that an implant-supported prosthesis is
not a guarantee for uncompromised oral function after
head and neck oncology treatment, but can be considered
a significant factor contributing to the well-being of these
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